Literature DB >> 15558223

Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis.

Jens Fielitz1, Manuela Leuschner, Heinz Renee Zurbrügg, Britta Hannack, Reinhard Pregla, Roland Hetzer, Vera Regitz-Zagrosek.   

Abstract

Aortic stenosis (AS) results in myocyte and extracellular matrix remodeling in the human left ventricle (LV). The myocardial renin-angiotensin system is activated and collagens I and III and fibronectin accumulate. We determined the yet unknown regulation of enzymes that control collagen turnover, i.e., LV matrix metalloproteinases (MMP) and their tissue inhibitors (TIMPs) in human AS. We compared LV samples from AS patients undergoing elective aortic valve replacement (n=19) with nonused donor hearts with normal LV function (controls, n=12). MMP-2, MMP-9, MT1-MMP, and extracellular matrix metalloproteinase inducer (EMMPRIN), TIMP-1, TIMP-2, TIMP-3, and TIMP-4 mRNA were quantitated by real-time RCR. MMP-1, MMP-2, MMP-3, TIMP-3, TIMP-4, and EMMPRIN protein were measured by immunoblotting and MMP-9 and TIMP-1 protein by ELISA. Gelatinolytic MMP-2 and MMP-9 activity was measured by zymography. MMP-2 was increased in AS at mRNA, protein, and activity levels (131%, 193%, and 138% of controls). MMP-3 protein (308%) and EMMPRIN mRNA and protein were also upregulated (171% and 200%). In contrast, MMP-1 (37%) and MMP-9 mRNA, protein, and activity (26%, 21%, and 52%) were downregulated. MMP-9 activity was inversely correlated with LV size. TIMP-1 mRNA and protein were decreased (55% and 73%). In contrast, TIMP-2 mRNA (358%), TIMP-3 mRNA and protein (145% and 249%) were increased. TIMP-4 mRNA was not altered, but TIMP-4 protein was upregulated to 350%. Changes were similar in AS patients with normal and impaired LV ejection fraction. The dysregulation of myocardial MMPs and TIMPs in human AS starts at an early disease stage when LV function is still normal. In spite of upregulation of some MMPs the balance between MMP and TIMP is shifted towards MMP inhibition in human AS and may contribute to collagen accumulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15558223     DOI: 10.1007/s00109-004-0606-4

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  53 in total

1.  TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).

Authors:  M Kashiwagi; M Tortorella; H Nagase; K Brew
Journal:  J Biol Chem       Date:  2001-01-23       Impact factor: 5.157

2.  Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression.

Authors:  C M Overall; J L Wrana; J Sodek
Journal:  J Biol Chem       Date:  1991-07-25       Impact factor: 5.157

Review 3.  Relating matrix metalloproteinase structure to function: why the "hemopexin" domain?

Authors:  G Murphy; V Knäuper
Journal:  Matrix Biol       Date:  1997-03       Impact factor: 11.583

4.  TGF-beta 1 attenuates myocardial ischemia-reperfusion injury via inhibition of upregulation of MMP-1.

Authors:  Hongjiang Chen; Dayuan Li; Tom Saldeen; Jawahar L Mehta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05       Impact factor: 4.733

Review 5.  Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease.

Authors:  C Ries; P E Petrides
Journal:  Biol Chem Hoppe Seyler       Date:  1995-06

Review 6.  Activation mechanisms of matrix metalloproteinases.

Authors:  H Nagase
Journal:  Biol Chem       Date:  1997 Mar-Apr       Impact factor: 3.915

7.  Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation.

Authors:  M L Coker; J R Jolly; C Joffs; T Etoh; J R Holder; B R Bond; F G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-08       Impact factor: 4.733

Review 8.  Preclinical and clinical studies of MMP inhibitors in cancer.

Authors:  A H Drummond; P Beckett; P D Brown; E A Bone; A H Davidson; W A Galloway; A J Gearing; P Huxley; D Laber; M McCourt; M Whittaker; L M Wood; A Wright
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

9.  Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure.

Authors:  V S Mujumdar; S C Tyagi
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

10.  Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling.

Authors:  Francisco J Villarreal; Michael Griffin; Jeffrey Omens; Wolfgang Dillmann; Judy Nguyen; James Covell
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

View more
  14 in total

1.  EMMPRIN activates multiple transcription factors in cardiomyocytes, and induces interleukin-18 expression via Rac1-dependent PI3K/Akt/IKK/NF-kappaB andMKK7/JNK/AP-1 signaling.

Authors:  Balachandar Venkatesan; Anthony J Valente; Sumanth D Prabhu; Prakashsrinivasan Shanmugam; Patrice Delafontaine; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2010-06-09       Impact factor: 5.000

2.  Endogenous nitric oxide formation correlates negatively with circulating matrix metalloproteinase (MMP)-2 and MMP-9 levels in black subjects.

Authors:  Ingrid F Metzger; Valéria C Sandrim; Jose E Tanus-Santos
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

3.  Matrix metalloproteinases and their regulators are cardiovascular therapeutic targets.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2004-12       Impact factor: 4.599

4.  LV reverse remodeling imparted by aortic valve replacement for severe aortic stenosis; is it durable? A cardiovascular MRI study sponsored by the American Heart Association.

Authors:  Robert W W Biederman; James A Magovern; Saundra B Grant; Ronald B Williams; June A Yamrozik; Diane A Vido; Vikas K Rathi; Geetha Rayarao; Ketheswaram Caruppannan; Mark Doyle
Journal:  J Cardiothorac Surg       Date:  2011-04-14       Impact factor: 1.637

Review 5.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

6.  High glucose and homocysteine synergistically affect the metalloproteinases-tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts.

Authors:  A Solini; E Santini; M Nannipieri; E Ferrannini
Journal:  Diabetologia       Date:  2006-08-01       Impact factor: 10.122

Review 7.  Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications.

Authors:  William M Yarbrough; Rupak Mukherjee; John S Ikonomidis; Michael R Zile; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-16       Impact factor: 5.209

Review 8.  Calcific Aortic Valve Disease: Part 2-Morphomechanical Abnormalities, Gene Reexpression, and Gender Effects on Ventricular Hypertrophy and Its Reversibility.

Authors:  Ares Pasipoularides
Journal:  J Cardiovasc Transl Res       Date:  2016-05-16       Impact factor: 4.132

9.  Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction.

Authors:  D Kelly; S Khan; G Cockerill; L L Ng; M Thompson; N J Samani; I B Squire
Journal:  Eur J Heart Fail       Date:  2008-01-30       Impact factor: 15.534

10.  17beta-Estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblasts.

Authors:  Shokoufeh Mahmoodzadeh; Elke Dworatzek; Stephan Fritschka; Thi Hang Pham; Vera Regitz-Zagrosek
Journal:  Cardiovasc Res       Date:  2009-10-27       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.